



## MAYNE PHARMA ANNOUNCES GRANT OF TWO ADDITIONAL PATENTS FOR NEXTSTELLIS® ORAL CONTRACEPTIVE

---

Patents are US FDA Orange Book listed with protection through June 17, 2036

**10 May 2024, Adelaide, Australia:** Mayne Pharma Group Limited (ASX: MYX) today announced that the U.S. Patent and Trademark Office has granted US Patent Nos. 11,964,055 ('055) and 11,957,694 ('694). The patents, which are US FDA Orange Book listed, provide additional protection to the NEXTSTELLIS® formulation. Both newly listed patents ('055 and '694) will expire June 17, 2036.

**Mayne Pharma CEO Shawn Patrick O'Brien said:** "NEXTSTELLIS® is the flagship product in our Women's Health Portfolio, and we are thrilled about the issuance of these new patents."

**In addition, Mayne Pharma EVP, Leader of Women's Health Lynn Sullivan said:** "These patents, complement our existing portfolio while enhancing our intellectual property strategy for this differentiated oral contraceptive. NEXTSTELLIS® continues to show the highest growth rate in the US branded OC market.<sup>1</sup> We will continue to advance our mission of ensuring that patients have access to this important product."

Licensed from Estetra SRL, a subsidiary of Mithra Pharmaceuticals SA, NEXTSTELLIS® is the first and only contraceptive pill containing a new low impact<sup>2</sup> estrogen, estetrol (E4), and a progestin, drospirenone. E4 is a natural estrogen produced by the human body during pregnancy and in NEXTSTELLIS® it is derived from a plant source. E4 is the first new estrogen introduced in the US in more than 60 years.

For further information contact:

Australia:  
Craig Haskins  
+61 421 029 843  
[ir@maynepharma.com](mailto:ir@maynepharma.com)

USA:  
Lisa M. Wilson  
+1 917-543-9932  
[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Chair

### About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe, and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug

---

<sup>1</sup> Based on IQVIA data of (Sept '23 to March '24)

<sup>2</sup> Based on its selectivity, potency, pharmacokinetics, mechanism of action and impact on the liver.

### Mayne Pharma Group Limited

ABN 76 115 832 963

[maynepharma.com](http://maynepharma.com)

1538 Main North Road, Salisbury South, SA 5106 Australia



## ASX Announcement

delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com).

NEXTSTELLIS® is a registered trademark of Estetra SRL, a Mithra Pharmaceuticals company.

